Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase I Study

Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced the first patient has been dosed by GlaxoSmithKline in the Phase I study of GSK4381562 in patients with solid tumors.